CD79b CAR-T therapy for relapsed B-cell leukemia or lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new type of CAR-T cell therapy that targets a protein called CD79b on cancer cells, hoping to destroy them in people with B-cell leukemia or lymphoma that hasn't responded to standard treatment. The cells are made from your own blood and given back to you to boost your immune system's ability to fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have B-cell acute lymphoblastic leukemia (B-ALL) or a B-cell lymphoma that has come back or not responded to treatment.
- You need to have some cancer cells in your bone marrow or blood (for leukemia) or at least one tumor that can be measured (for lymphoma).
- Your liver, kidney, and heart function need to be within safe ranges.
- You must be able to manage daily activities (ECOG 0-2) and have an expected survival of at least 3 months.
- You cannot have had CAR-T therapy before, active infections like HIV, hepatitis B/C, or certain heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special type of immune therapy called CD19-BAFF CAR-T cells for people whose B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma has come back or not responded to standard treatment. The therapy uses your own modified immune cells to target and kill cancer cells.
This early-phase study tests a treatment called CD19 CAR-T, made from your immune cells, for people whose CD19+ blood cancer has come back or did not respond. It may help your body better recognize and attack cancer cells, but eligibility is tight and the study is still early.
This trial tests a new CAR-T cell therapy that targets a protein called CD19 on leukemia cells. It's designed for people with relapsed or refractory B-cell acute lymphoblastic leukemia (a type of blood cancer) that hasn't responded to standard treatments.
This trial tests a new type of CAR-T cell therapy designed to be stronger against B-cell lymphoma that has come back or not responded to previous treatments. The treatment uses your own immune cells, which are modified in a lab to better attack cancer cells.
This early-phase trial tests a special kind of immune cell treatment (CAR T cells) that targets CD20 and CD22 in people with relapsed or refractory B-cell cancers. It may help by attacking cancer cells that survived prior treatments, but it is still being studied for safety and early effectiveness.
This trial tests a new type of immune cell therapy called CAR-T cells that are designed to find and destroy cancer cells with the CD19 or CD22 markers. The goal is to see if this experimental treatment can help people with B-cell acute lymphoblastic leukemia or non-Hodgkin's lymphoma when other treatments haven't worked.
Hear when a new Relapsed and/or Refractory Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.